Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber Trial

Purpose: The primary objective was to assess the acute efficacy of 0.25% reproxalap ophthalmic solution versus vehicle in patients with dry eye disease. Design: This was a vehicle-controlled, randomized-sequence, double-masked, 2-period crossover trial. Participants and Controls: Sixty-three patient...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Sumit Garg, MD, Eric Donnenfeld, MD, John Sheppard, MD, Alice Epitropoulos, MD, Todd C. Brady, MD, PhD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-01-01
Serija:	Ophthalmology Science
Teme:	Dry eye chamber Dry eye disease Ocular redness Reactive aldehyde species Reproxalap
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2666914525002362
Oznake:	Označite Brez oznak, prvi označite!